摘要
In DNA-guided hepatitis B treatment, viral load is insufficient, and requires other viral markers for treatment of hepatitis B patients as in patients with acute exacerbation of chronic hepatitis B, end-stage renal disease on dialysis, human immunodeficiency virus co-infected patients. There are exceptions to this rule： a residual level hepatitis B virus （HBV） DNA at 24 wk predicts beneficial outcome and reduced resistance at i year. The genotypic viral resistance to antiviral agents and occult HBV infection can be determined by HBV-DNA levels.
In DNA-guided hepatitis B treatment,viral load is insufficient,and requires other viral markers for treatment of hepatitis B patients as in patients with acute exacerbation of chronic hepatitis B,end-stage renal disease on dialysis,human immunodeficiency virus co-infected patients.There are exceptions to this rule:a residual level hepatitis B virus(HBV)DNA at 24 wk predicts beneficial outcome and reduced resistance at 1 year.The genotypic viral resistance to antiviral agents and occult HBV infection can be determined by HBV-DNA levels.
